Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Cemiplimab Recombinant Human Monoclonal Antibody
Human Recombinant Monoclonal Antibody
Supplier: Invitrogen™ MA542208
This item is not returnable.
View return policy
Description
Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.
Cemiplimab is a fully human PD-1 antibody. The first indication for the marketing application is metastatic/locally advanced cutaneous squamous cell carcinoma (Cutaneous Squamous Cell Carcinoma, CSCC). It is an intravenous immunotherapy targeting the PD-1 pathway, which can help the immune system fight cancer cells.
Specifications
Cemiplimab | |
Recombinant Monoclonal | |
Unconjugated | |
cemiplimab-rwlc; REGN-2810; SAR-439684 | |
Human PDCD1/PD1/CD279. | |
100 μg | |
Primary | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid | |
Chemical |
ELISA, SDS-Page | |
1.65 mg/mL | |
PBS with no preservative; pH 7.5 | |
Human | |
Protein A | |
RUO | |
Human | |
Antibody | |
IgG4 κ |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction